Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-4083 (Flubentylosin) in Onchocerciasis
NCT04913610Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Classical Binding Small Molecules, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Flubentylosin in onchocerciasis, sponsored by AbbVie Inc.. Started May 2021; status: terminated.
02
Drugs
Flubentylosin
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on NCT04913610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913610.